10/26/2026
Regulatory approval is not the same as readiness to deliver care.
That was a central theme at Horizons in New York City last week, where Sunstone Co-Founder Kimberly Roddy joined a panel on Clinics and Care: Preparing for Patients.
As investigational psychedelic therapies move closer to potential approval, much of the conversation is focused on the medicines themselves. But approval alone won't create the clinical infrastructure needed to deliver them: trained teams, appropriate facilities, reimbursement pathways, and the capacity to support patients before, during, and after treatment must be built in parallel.
At Sunstone, our experience across myriad clinical trials has shown us how complex that care can be.
Some participants may need relatively little support after a dosing session; others, considerably more. Understanding those differences, and how to respond, is essential as we consider bringing these treatments into everyday healthcare settings.
The challenge isn't to replicate every aspect of a clinical trial. It's to understand which elements of care we need to preserve, where we can responsibly create efficiencies, and what additional evidence we need to make those decisions.
Making these therapies more accessible will require more than making the medicines available. It will require care models that can accommodate different patient needs, support the clinicians delivering treatment, and work within the realities of healthcare reimbursement.
We're grateful to Horizons and our fellow panelists for a thoughtful discussion about what it will take to move from promising research toward responsible clinical care.
